(Q35061290)

English

Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

multiple sclerosis

0 references

author name string

Johan Mellergård

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Måns Edström

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Maria C Jenmalm

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Charlotte Dahle

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Magnus Vrethem

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jan Ernerudh

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

2 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

e81685

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

2 December 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

The evidence for a role of B cells in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Role of the innate immune system in the pathogenesis of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

The significance of OX40 and OX40L to T-cell biology and immune disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Effects of natalizumab treatment on Foxp3+ T regulatory cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

NK cells at the interface between innate and adaptive immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Adhesion molecules in autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Lymphoblastic transformation in response to viral antigens in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

8 July 2018

Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0081685

21 January 2018

Immune surveillance in multiple sclerosis patients treated with natalizumab.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0081685

21 January 2018

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0081685

21 January 2018

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0081685

21 January 2018

Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0081685

21 January 2018

Systemic reduction of functionally suppressive CD4dimCD25highFoxp3+ Tregs in human second trimester pregnancy is induced by progesterone and 17beta-estradiol.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0081685

21 January 2018

Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0081685

21 January 2018

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0081685

21 January 2018

Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0081685

21 January 2018

B cells undergo unique compartmentalized redistribution in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0081685

21 January 2018

Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

27 September 2018

Natalizumab effects on immune cell responses in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847051

27 September 2018

Lymphocyte blast transformation responses and viral antibodies in relation to HLA antigens in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24312575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defective CD3 mediated proliferation and LPS responsiveness in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24312575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24312575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phenotypic and functional characterization of human CD25+ B cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24312575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24312575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

1 reference

https://pubmed.ncbi.nlm.nih.gov/24312575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24312575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0081685

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2013PLoSO...881685M

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35061290&oldid=1863368693"